Immune cell therapy tested for tough childhood cancers
NCT ID NCT03420963
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a treatment using donated natural killer (NK) cells from cord blood, combined with chemotherapy, for children and young adults with solid tumors that returned or didn't respond to standard care. The goal was to find the safest dose and check for side effects. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Vaccine trains immune system to hunt down cancer cells
- Tiny paclitaxel particles aim to hit tumors harder
- New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
- Keytruda takes on genetic weak spots in advanced tumors
- New drug targets tough childhood cancers with genetic flaws
- Targeted drug takes aim at NF1-Mutated cancers